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Abstract 
Cirrhosis and hepatocellular carcinoma (HCC) end-stages of chronic liver diseases (CLD) are 
leading causes of morbidity and mortality worldwide. The main aetiologies of CLDs are 
chronic hepatitis C virus (HCV) infection. The aim of this work was to evaluate fibrotic indices 
APRI and FIB-4 in patients with chronic liver disease (CLD) with HCC, Cirrhosis, and healthy 
individuals. In the present study, we have investigated 30 Hepatocellular Carcinoma (HCC) 
patients, from Gastroenterology Center, Mansoura University, compared with 17 cirrhotic 
patients, and 25 normal healthy individuals as a control group. Laboratory liver fibrosis indices 
including FIB-4, APRI, and AST/ALT ratio were calculated in Egyptian patients with chronic 
hepatitis C virus. Results from this study were high APRI and FIB-4 in HCC patients 
compared with Cirrhosis and Control groups with significance difference (p<0.05). Based on 
our observation in this study APRI and FIB-4 which representing fibrotic indices have 
diagnostic value in the assessment of hepatocellular carcinoma. 
Keywords: Chronic Liver Diseases (CLD); HCV; Hepatocellular Carcinoma (HCC); AFP. 
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INTRODUCTION 
Hepatitis C virus (HCV) infection is a global public 
health burden. Approximately 170 million people are 
infected with HCV worldwide, and most of these patients 
become persistently infected. Furthermore, HCV infection 
in some patients may progress into chronic liver diseases, 
such as steatosis, cirrhosis, and hepatocellular carcinoma 
(Choo et al., 1989; Ali et al., 2015). HBV and HCV 
achieved an endemic situation in many countries of the 
world (Kalim et al., 2017). It is reported that elevation of 
liver enzymes is responsible for liver disorders (Toor et al., 
2016). The chronic liver abnormalities are often 
accompanied by indigestion, fatigue, weakness, fever, 
abdominal pain, nausea, and loss of appetite (Muhammad 
et al., 2013). In Egypt, hepatocellular carcinoma (HCC) is 
the second most common cancer in men and the 6th most 
common cancers in women. Hospital-based studies from 
Egypt have reported an overall increase in the relative 
frequency of all liver-related cancers in Egypt, from 
approximately 4% in 1993 to 7.3% in 2003. This rising 
incidence (Lehman et al., 2008) may be due to the high 
prevalence of hepatitis C virus (HCV) and its complications 
and the fact that people born 20 years ago or earlier in 
Egypt has not been vaccinated against hepatitis B virus 
(HBV) (Yates et al., 1999). Because of the prevalence, 
HCC is the most studied primary liver cancer. Several 
different histological subtypes are known such as scirrhous 
HCC, fibrolamellar carcinoma, combined HCC-
Cholangiocarcinoma (HCC-CC), sarcomatoid HCC, 
undifferentiated carcinoma, lymphoepithelioma-like HCC, 
clear cell HCC, diffuse cirrhosis-like HCC, steatohepatitis 
HCC, transitional liver cell tumor, and CAP carcinoma 
(Roncalli et al., 2010). The lack of useful molecular markers 
to classify HCC aggressiveness hereby complicates clinical 
analyses to stage patient’s outcomes (Okuda, 2000). 
Development of liver tumors and their evolution to HCC is a 
multi-step process where different HCC-etiologies provoke 
continuous rounds of hepatocytes damage and 
regeneration. These cycles of damage-death-regeneration 
lead to collagen accumulation contributing to liver fibrosis. 
Over an extended time, this triggers a cirrhotic state 
considered as a pathological state of the liver whose 
lesions can progress to a pre-malignant state producing 
dysplastic nodules. Later, these nodules will evolve to HCC 
invading the surrounding stroma and occasionally 
generating metastatic events (Borzio et al., 1995). 
Transcriptional analyses of liver tumors revealed alterations 
of several molecular pathways during cancer development 
implicated in cell proliferation, cell cycle regulation, 
apoptosis, (Hanahan and Weinberg, 2011) angiogenesis, 
cell signaling, metabolism, and immune response 
(particularly in HCC with HBV/HCV infection). 
Investigations in Egypt have shown the increasing 
importance of HCV infection in the etiology of liver cancer, 
estimated to account for 40-50% of cases, and the 
declining influence of HBV and HBV/HCV infection (25% 
and 15%, respectively). The rising incidence of HCC in 
Egypt could be explained through improvements in 
screening programs and diagnostic tools, as well as the 
increased survival rate among patients with cirrhosis 
allowing time for some of them to develop HCC (El-Serag, 
2001). The aim of this study was to determine diagnostic 
significance of fibrotic indices in Egyptian patients with 
chronic hepatitis and hepatocellular carcinoma. 
                                                        
MATERIALS AND METHODS 
Study design 
This study consisted of a total of 30 HCC patients 
recruited from Gastroenterology Center, Mansoura 
University were enrolled in this study represented the group 
I. They were diagnosed as HCC according to clinical 
examination, radiological investigations including 
abdominal ultrasonography, triphasic C.T, and laboratory 
investigations. There were 17 Cirrhotic patients 
representing group II. Additionally, healthy 25 subjects 
were enrolled in this study represented group III; they had 
normal values of serum alanine aminotransferase (ALT), 
aspartate aminotransferase (AST) and were seronegative 
for hepatitis B surface markers and HCV antibodies, HIV.  
 
Ethical approval 
The protocol was conducted in accordance with 
guidelines approved by local research ethics committee 
and the subjects in this study were matched in regard to 
sex and age and informed consent was obtained from all 
the patients and volunteers.   
 
Collection of samples and biochemical analyses 
Six milliliters of venous blood specimens were 
collected in dry clean centrifuge tubes after an overnight 
fast, left to clot for 30 minutes at 37°C, and then centrifuged 
at 3000 rpm for 10 minutes. The sera were then separated, 
divided into several aliquots, stored at -20°C to be thawed 
only once on demand for the biochemical analyses. CBC 
was carried out using automated cell counter Sysmex KX-
21N (TAO Medical incorporation, Japan). All patients and 
controls were subjected to full clinical assessment. 
Laboratory investigations included aspartate 
aminotransferase (AST), alanine transaminase (ALT), 
alkaline phosphatase (ALP), Alpha-fetoprotein (AFP), total 
bilirubin, and serum albumin. All were performed on 
Beckman CX9 autoanalyzer.   
 
Fibrotic Indices Calculation 
APRI = (AST / upper limit of normal AST) × 100 / 
platelet count) (Wai et al., 2003). 
FIB-4 = (AST × age / platelet counts × ALT 
1/2
) (Sterling 
et al., 2006). 
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Statistical analysis 
A computer software package (SPSS), version 16.0 
was used in the analysis. For quantitative variables, mean 
and median (as a measure of central tendency), the 
standard deviation was used. Frequency and percentage 
were presented for qualitative variables. Significance level 
(p) value was expressed as follows: p > 0.05 = Insignificant, 
p < 0.05 = Significant and p < 0.001 = highly significant. 
 
RESULTS  
Our results demonstrated that among 30 HCC 
patients, 23 (76.6%) were males and 7 females (23.3%), 
and their age ranged from 45-69 years with a mean of 
55.6±6.92 years. Among 17 patients with cirrhosis 
representing group II, 13 (76.5%) were males and 4 
females (23.5%), and their age ranged from 53-87. Among 
25 unrelated healthy adults representing group III with no 
liver diseases as a control group, 17 (68.0%) were males 
and 8 females (32.0%), and their age ranged from 23-37 
years with a mean of 26.8±3.014 years as shown in (Table 
1). Serum ALT and AST were higher in Cirrhotic patients 
comparing with HCC patients and control group with 
significance difference (p< 0.05). Serum APRI and FIB-4 
indices were higher in HCC patients compared with 
Cirrhotic and Control groups with significance difference 
(p< 0.05) as shown in (Table 2). Platelet count was higher 
in control group than patients (Figure 1). A previous study 
showed the levels of biochemical markers (AST, ALT, and 
bilirubin) of the liver fibrosis group were higher than healthy 
individual's groups (p < 0.001) (Canbakan et al., 2009). 
Giannini et al. (2006) found that AST/ALT ratios increased 
and platelet counts decreased as liver fibrosis worsened. 
The rates of HCC are consistently higher for males than 
females, but the male to female ratio differs with the 
country as well as with the year of survey, because of the 
changing time trends. In our study, HCC males were 
(76.6 %) while females with HCC were (23.3 %). The 
incidence of HCC increases progressively with age, 
although this varies by country. Thus, in high incidence 
countries, the mean age at the time of diagnosis is in the 
third decade of life, and in low incidence countries, it occurs 
2 to 3 decades later. In our study, the mean age of HCC 
patients, Cirrhotic patients, and healthy control was 55.6 ± 
6.92, 65.1 ± 11.7 and 26.8 ± 3.01 years, respectively. 
There was a significant difference between groups 
regarding the age distribution (Table 1). This finding was 
close to previous research by Massoud et al. (2006). In the 
present study, there was a significant positive correlation 
between ALT and AST (r=0.789, p<0.05) (Figure 2). APRI 
and FIB-4 were also found to have a significant positive 
correlation (r= 0.906 and P<0.05) (Figure 3). 
 
 
Table 1. Descriptive data in HCC, Cirrhosis and Control groups 
 
 
Table 2. Mean and S.D of biochemical parameters and fibrotic indices in HCC, Cirrhosis and Control groups 
 
Variables HCC 
Patients 
Cirrhotic 
Patients 
Healthy 
Control 
Number N= 30 N= 17 N= 25 
Age mean ± S.D 55.6 ±  6.92 65.1 ±  11.74 26.8 ±  3.014 
Range 45-69 53-87 23-37 
Male 23 (76.6 %) 13(76.5%) 17 (68.0 %) 
Female 7 (23.3 %) 4(23.5%) 8 (32.0 %) 
Variables HCC 
mean ± S.D 
Cirrhotic 
mean ± S.D 
Control 
mean ± S.D 
ALT (40 IU/L) 53.1 ± 41.2 65.9 ± 34.8 14.04 ± 3.39 
AST(40 IU/L) 65.3 ± 29.1 72.6 ± 20.0 15.6 ± 2.30 
AST/ALT index 1.59 ± 0.96 1.28 ± 0.54 1.14 ± 0.30 
APRI index 1.5  ± 1.03 0.79 ± 0.51 0.12 ± 0.03 
FIB-4 index 4.8 ± 2.73 2.33 ± 1.15 0.36 ± 0.12 
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Fig. 1. Mean values of biochemical parameters and fibrotic indices in all groups. 
 
 
 
 
 
 
 
Fig. 2. Pearson Correlation between AST and ALT 
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Fig. 3. Pearson Correlation between APRI and FIB-4 
 
 
 
In this study there was a significant difference between 
the concentration of AFP in both HCC patients and Control, 
there was a high concentration of AFP in HCC patients with 
mean 4.78 ±7.42 and ranged between 0.8 – 2000 ng/ml 
compared with healthy control groups with mean 2.7±0.55 
and ranged between 1.5-4.0 ng/ml (Table 3). In our study 
for detection of specificity and sensitivity, ROC was 
estimated and AUROC was (0.8, p <0.05) (Figure 4). 
Alpha-fetoprotein (AFP) is a glycoprotein with a size of 591 
amino acids. It is normally synthesized during fetal life, first 
in the yolk sac and then in the fetal liver; its synthesis is 
normally repressed in adults. High levels of AFP are 
observed during adulthood only under certain conditions, 
such as pregnancy, the presence of some neoplasias (e.g. 
HCC, gastric carcinoma, testicular carcinoma, lung cancer 
and pancreatic cancer and some non-neoplastic disorders 
such as HC and hepatitis (Soresi et al., 2003). The 
association between serum AFP and HCC has been widely 
examined and described by a large number of groups. 
Regardless, its sensitivity and specificity for diagnosing 
HCC are variable, with figures ranging from 39 to 73% and 
65 to 96%, respectively (Forner et al., 2009) depending on 
factors such as the specific assay used, the design of the 
study, the characteristics of the study population, and the 
designated cut-off level (Huo et al., 2007). The chronic 
hepatic disease damages the liver and the resulting wound-
healing process might lead to liver fibrosis and subsequent 
cirrhosis development. Fibrosis is the excessive deposition 
of extracellular matrix in the tissue as consequence of 
chronic liver damage. Thus, efforts to understand and 
attenuate fibrosis have direct clinical implications (Mas et 
al., 2009). Clinical management of chronic hepatitis C is 
dependent on the extent of liver fibrosis. Liver biopsy, the 
gold standard, is still recommended in the majority of 
patients (Strader et al., 2004). However, it is an invasive 
procedure responsible for severe complications in about 
0.5% of cases. Sample variability is another limitation. 
 
 
 
Table 3. Showing AFP in HCC and Control groups 
Groups Median Minimum Maximum P value 
HCC  Patients 30.6 0.8 2000  
P<0.05 
Healthy Control 3.0 1.5 4.0 
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Fig. 4. ROC curve for AFP area under the curve (AUROC) 0.891, p <0.05 
 
 
 
CONCLUSION 
Hepatitis C virus (HCV) has been estimated by the 
World Health Organization (WHO) to infect 170 million 
patients worldwide, with the highest prevalence rate among 
Egyptians (14%-18%, approximately 10-fold greater than in 
the United States and Europe) it accounts for most chronic 
liver disease and HCC cases in Egypt. Hepatocellular 
carcinoma (HCC) is the third cause of death among those 
patients with malignant tumors. Chronic infection by 
hepatitis B or C virus (HBV and HCV) is the principal risk 
factors for HCC. Early diagnosis of HCC is the only hope 
for a cure, as most patients have the inoperable disease at 
the time of diagnosis. There was a correlation between 
APRI and FIB-4 fibrotic indices, Also Fibrotic Indices 
including APRI and FIB-4 are a non-invasive tool with 
diagnostic value and could differentiate between 
Hepatocellular, Cirrhotic patients. 
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